REG - GSK PLC - ViiV completes changes to minority shareholding

GSKAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA8785Ya&default-theme=true

RNS Number : 8785Y  GSK PLC  01 April 2026

 

Issued: 1 April 2026, London UK

 

GSK, Pfizer and Shionogi complete changes to ViiV Healthcare shareholding

·   Completion of Pfizer's exit of its investment in ViiV Healthcare

·   Increase of Shionogi's holding to 21.7%, with GSK maintaining 78.3%
majority share

 

 

GSK plc (LSE/NYSE: GSK) ("GSK"), and Shionogi & Co., Ltd (Head Office:
Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) ("Shionogi"),
further to their announcements on 20 January 2026, announce the completion of
the transaction for the 11.7% economic interest in ViiV Healthcare Limited
("ViiV Healthcare") previously held by Pfizer Inc. (NYSE: PFE) ("Pfizer") to
be replaced with an investment by Shionogi. As a result of this transaction,
Shionogi has increased its economic interest in ViiV Healthcare to 21.7%. GSK
maintains its 78.3% majority owned economic interest.

 

ViiV Healthcare issued new shares to Shionogi for consideration of $2.125 bn
and cancelled Pfizer's holding in ViiV Healthcare. Pfizer received $1.875 bn
and GSK received a special dividend of $0.250 bn (paid in GBP).

 

Financial Considerations

The Pfizer put option liability shown in GSK's accounts for the year ended 31
December 2025 was extinguished through retained earnings at completion. The
put option liability was remeasured immediately prior to completion on the
same methodology as at 31 December 2025, with the fair value change in the
liability recognised as an adjusting item through other operating income.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(https://www.gsk.com) .

 

About Shionogi

Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical
company dedicated to bringing benefits to patients based on its corporate
philosophy of "supplying the best possible medicine to protect the health and
well-being of the patients we serve." Shionogi has discovered and developed
novel antibiotics, medicines for HIV and influenza, and currently markets
medicines for infectious diseases and central nervous system disorders. For
more information, visit https://www.shionogi.com/global/en
(https://www.shionogi.com/global/en) .

 

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November
2009 dedicated to delivering advances in treatment and care for people living
with HIV and for people who could benefit from HIV prevention. The company's
aims are to take a deeper and broader interest in HIV and AIDS than any
company has done before and take a new approach to deliver effective and
innovative medicines for HIV treatment and prevention, as well as support
communities affected by HIV.

 

For more information on the company, its management, portfolio, pipeline, and
commitment, please visit viivhealthcare.com (https://viivhealthcare.com/) .

 

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are
based on expectations in light of the information currently available and
assumptions that are subject to risks and uncertainties which could cause
actual results to differ materially from these statements. These risks and
uncertainties particularly apply with respect to transaction-related
forward-looking statements. GSK and Shionogi disclaim any intention or
obligation to update or revise any forward-looking statements whether as a
result of new information, future events or otherwise.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Sarah Clements     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Sam Piper          +44 (0) 7824 525779   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Shionogi enquiries

Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
(https://www.shionogi.com/global/en/contact.html)

 

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFEIVIILVIR



            Copyright 2019 Regulatory News Service, all rights reserved